Our results showed that pNaKtide treatment increased hepatic expression of genes involved in fatty acid oxidation including CPT-1, PGC1α and LCAD in the setting of caloric excess, to ameliorate the NASH phenotype. The gene discussed is ACADL; the disease is metabolic dysfunction-associated steatohepatitis.